While the bulk of the Listeria cancer immunotherapy literature has focused on eliciting anti-tumor adaptive immunity, little focus has been directed to the modulation of the innate, immunosuppressive populations present in the tumor treatment with toll-like receptor (TLR) agonists alone does not confer survival